Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
Librax is a fixed-dose combination of chlordiazepoxide (a benzodiazepine) and clidinium bromide (an anticholinergic) approved in 1966 for oral use as a capsule. It is indicated for adjunctive treatment of gastrointestinal disorders such as irritable bowel syndrome and peptic ulcer disease, combining anxiolytic and antispasmodic properties.
This legacy product is in late-stage decline with minimal Part D claims (1,061 in 2023), indicating a shrinking team and limited growth opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Post Market (Libra/LibraXP System) Deep Brain Stimulation (DBS) Parkinson's Disease Study
Working on Librax offers limited career growth; the product is in terminal decline with zero linked job openings and minimal commercial activity. Professionals should expect a support-and-defend role managing existing patient relationships rather than launching or scaling a product.
Worked on LIBRAX at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo